Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Provectus Biopharmaceuticals, Inc.

http://www.provectusbio.com/

Latest From Provectus Biopharmaceuticals, Inc.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Otsuka Counts The Cost Of Alzheimer’s Agitation Fail

The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.

Clinical Trials Neurology

Towa Buys Out Kamata Following Facility Expansion And Guidance Raise

Japanese generics firm Towa has acquired Kamata as a wholly owned subsidiary, in order to increase soft capsule manufacturing capacity for its Sunsho segment. The firm has also announced that it has completed expansion works at its Yamagata plant and made a moderate revision to its financial forecast.

Generic Drugs Strategy

Breakdowns In The Breakthrough Lane: When Recipients Of FDA Expedited Designation Fall Short

Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.

US FDA Performance Tracker Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Medical Devices
    • Laser
  • Other Names / Subsidiaries
    • Provectus Biopharmaceuticals Australia Pty Ltd.
    • Provectus Pharmaceuticals, Inc.
UsernamePublicRestriction

Register